It may have listings in Hong Kong and Shanghai, but cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) is making it clear it wants to keep its original listing in the U.S. that is currently under threat due to U.S.-China tensions.
作者陽歌，本文僅代表作者個人觀點
您已閱讀3%（256字），剩余97%（7786字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。